United States

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

6:17am EDT
Change (% chg)

Rs-29.40 (-3.84%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Sun Pharmaceutical Industries Ltd announces commences Tender Offer for Acquisition of InSite Vision
Tuesday, 29 Sep 2015 08:46am EDT 

Sun Pharmaceutical Industries Ltd:Announces has commenced a tender offer thruough its indirect wholly owned subsidiary,Thea Acquisition Corporation, for all of the outstanding shares of common stock of InSite Vision Incop. for $0.35 per share in cash, without interest and less any required withholding taxes.  Full Article

Sun Pharmaceutical Industries Ltd acquires CNS divisions of erstwhile Ranbaxy
Monday, 21 Sep 2015 04:12am EDT 

Sun Pharmaceutical Industries Ltd:Says Sun Pharmaceutical Industries Ltd and Strides Arcolab Ltd announces that they have entered into a definitive agreement related to erstwhile Ranbaxy’s ‘Solus’ and ‘Solus Care’ divisions operating in the central nervous system (CNS) segment in India.Says the agreement involves transfer of these two marketing divisions, along with employees to Strides for a consideration of Rs. 1,650 million.  Full Article

InSite Vision Inc and Sun Pharmaceutical Industries Ltd enter into merger agreement
Tuesday, 15 Sep 2015 04:24pm EDT 

InSite Vision Inc:Insite Vision and Sun Pharma enter into merger agreement.Deal for $0.35 per share or approximately $48 million in aggregate equity value.Says Under the terms of the merger agreement, an indirect wholly owned subsidiary of Sun Pharma will commence a tender offer for all outstanding shares of InSite at $0.35 per share in cash.Acquisition is expected to close in the fourth quarter.  Full Article

Sun Pharmaceutical Industries completes acquisition of opiates business in Australia
Monday, 31 Aug 2015 10:55pm EDT 

Sun Pharmaceutical Industries Ltd:Sun pharma announces successful completion of opiates business acquisition in Australia.Significantly expands NRM capability through two opiates manufacturing facilities in Australia.Acquisition also brings a specialized team to drive business growth.Opiates acquisition to enhance opiate alkaloids portfolio and depth in global opiates market.  Full Article

Sun Pharmaceutical Industries Ltd recommends Dividend
Tuesday, 11 Aug 2015 07:34am EDT 

Sun Pharmaceutical Industries Ltd:Has recommends payment of dividend of 3 Indian Rupees per equity share of 1 Indian Rupees each for the year ended March 31, subject to the approval of the members at the ensuing Annual General Meeting to be held in around end of October 2015.  Full Article

Sun Pharmaceutical Industries Ltd and AstraZeneca enter into distribution agreement for ticagrelor in India
Monday, 1 Jun 2015 11:09pm EDT 

Sun Pharmaceutical Industries Ltd:Announces that AZPIL and Sun Pharma have entered into a distribution services agreement in India for AstraZeneca’s brand 'Axcer', a new brand of ticagrelor, a drug used for the treatment of acute coronary syndrome (ACS).Says AZPIL already has a brand under the trademark 'Brilinta', for ticagrelor molecule, launched and marketed by AZPIL in India since 2012.Says Sun Pharma will be promoting and distributing 'Axcer' brand in India.Says this collaboration enables AstraZeneca to expand usage of this molecule through wider reach to physicians and thereby benefiting a greater number of ACS patients.Says It strengthens Sun Pharma’s cardiology portfolio with the addition of a new patented therapy.  Full Article

Sun Pharmaceutical Industries Ltd settles Angiomax litigation with The Medicines Company - The Economic Times
Wednesday, 1 Apr 2015 11:28am EDT 

Sun Pharmaceutical Industries Ltd:Has entered into a settlement pact with The Medicines Company for settling the lawsuit filed against it by the later for generic Angiomax - The Economic Times.The company and certain of its subsidiaries have executed a settlement agreement with The Medicines Company settling the lawsuit filed against the company and its subsidiaries regarding submission of ANDA by one of subsidiaries, for a generic version of Angiomax, Bivalirudin injection.Under the terms of the agreement, the company's subsidiary is entitled to launch its version of generic Angiomax in the US on June 30, 2019 or earlier under certain limited circumstances.  Full Article

Sun Pharmaceutical Industries Ltd announces closure of merger deal with Ranbaxy
Wednesday, 25 Mar 2015 07:29am EDT 

Sun Pharmaceutical Industries Ltd:Begins integration of Ranbaxy's business following closure of its merger.Says integration, planned by Sun Pharma over many months, will focus on supporting strong growth.Says merger has fortified Sun Pharma's position as world's fifth largest specialty generic pharmaceutical company and top ranking Indian Pharma company with significant lead in market share.Says combined entity's manufacturing footprint covers 5 continents with products sold in over 150 nations with stronger presence in US, India, Asia, Europe, South Africa, CIS & Russia and Latin America.Sun Pharma now offers large basket of specialty and generic products encompassing a broad range of chronic and acute prescription drugs as well as a ready foray into the global consumer healthcare market.Post-merger, Daiichi Sankyo becomes the second largest shareholder in Sun Pharma and both companies will work together to leverage this relationship for global business growth.Says integrated culture theme, "Growing Together", represents the core objective of this merger focusing on improving productivity, compliance commitment, focus on quality and sustainable growth.Through this merger Sun Pharma emerges as India's first truly global pharmaceutical company.  Full Article

Sun Pharmaceutical Industries Ltd recalls 5,322 bottles of Ketorolac eye drop in US - The Economic Times
Sunday, 8 Mar 2015 01:13am EST 

Sun Pharmaceutical Industries Ltd:Is voluntarily recalling 5,322 bottles of Ketorolac Tromethamine ophthalmic solution in the US market for failing to meet specifications - The Economic Times.As per the information available on the USFDA website, Sun Pharma Global Fze, a US-based unit of the company, is recalling the eye drops for 'presence of particulate matter' in the 5,322 batch of bottles.The drug was manufactured by Sun Pharmaceutical Industries at its Halol facility in Gujarat and distributed by Caraco Pharmaceutical Laboratories in the US market.The recall was initiated by the company on Jan. 21 this year.It has been classified as a 'Class-II recall.  Full Article

Sun Pharmaceutical Industries Ltd to buy GlaxoSmithKline Plc's Opiates business in Australia
Monday, 2 Mar 2015 09:48pm EST 

GlaxoSmithKline Plc and Sun Pharmaceutical Industries Ltd:Announced that their respective wholly owned subsidiaries have reached an agreement related to GSK's Opiates business in Australia.Current GSK Opiates business including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria) and its portfolio of opiates products along with inventory, will transfer to a subsidiary of Sun Pharma.Product portfolio consists of poppy-derived opiate raw materials that are primarily used in manufacture of analgesics for treatment of moderate to severe pain.Says that all employees from both sites will also be offered employment by Sun with the Opiates business.Financial terms of transaction are confidential.Transaction is expected to close by Aug.  Full Article

EU court to rule on drugmaker Lundbeck's pay-for-delay deals

Europe's top court will rule on Thursday whether Danish drugmaker Lundbeck breached EU antitrust rules by paying smaller rivals to delay generic copies of its blockbuster citalopram anti-depressant from entering the market.